Department of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada.
The Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Washington, DC.
Diabetes Care. 2022 Mar 1;45(3):585-593. doi: 10.2337/dc21-1883.
Rapid loss of estimated glomerular filtration rate (eGFR) within its normal range has been proposed as a strong predictor of future kidney disease. We investigated this association of eGFR slope early in the course of type 1 diabetes with long-term incidence of kidney and cardiovascular complications.
The annual percentage change in eGFR (slope) was calculated during the Diabetes Control and Complications Trial (DCCT) for each of 1,441 participants over a mean of 6.5 years and dichotomized by the presence or absence of early rapid eGFR loss (slope ≤-3% per year) as the exposure of interest. Outcomes were incident reduced eGFR (eGFR <60 mL/min/1.73 m2), composite cardiovascular events, or major adverse cardiovascular events (MACE) during the subsequent 24 years post-DCCT closeout follow-up.
At DCCT closeout (the baseline for this analysis), diabetes duration was 12 ± 4.8 years, most participants (85.9%) had normoalbuminuria, mean eGFR was 117.0 ± 13.4 mL/min/1.73 m2, and 149 (10.4%) had experienced early rapid eGFR loss over the preceding trial phase. Over the 24-year subsequent follow-up, there were 187 reduced eGFR (6.3 per 1,000 person-years) and 113 MACE (3.6 per 1,000 person-years) events. Early rapid eGFR loss was associated with risk of reduced eGFR (hazard ratio [HR] 1.81, 95% CI 1.18-2.79, P = 0.0064), but not after adjustment for baseline eGFR level (HR 0.94, 95% CI 0.53-1.66, P = 0.84). There was no association with composite cardiovascular events or MACE.
In people with type 1 diabetes primarily with normal eGFR and normoalbuminuria, the preceding slope of eGFR confers no additional association with kidney or cardiovascular outcomes beyond knowledge of an individual's current level.
在正常范围内估算肾小球滤过率(eGFR)的快速下降被认为是未来肾脏疾病的一个强有力的预测指标。我们研究了 1 型糖尿病病程早期 eGFR 斜率与长期肾脏和心血管并发症发生之间的这种关联。
在糖尿病控制和并发症试验(DCCT)中,对 1441 名参与者的 eGFR (斜率)在平均 6.5 年期间的年度百分比变化进行了计算,并根据是否存在早期快速 eGFR 下降(斜率≤-3%/年)将其分为暴露组。结果为 eGFR 降低(eGFR<60mL/min/1.73m2)、复合心血管事件或主要不良心血管事件(MACE),在 DCCT 结束后 24 年的后续随访期间发生。
在 DCCT 结束时(本分析的基线),糖尿病病程为 12±4.8 年,大多数参与者(85.9%)有正常白蛋白尿,平均 eGFR 为 117.0±13.4mL/min/1.73m2,149 名(10.4%)在试验前期经历了早期快速 eGFR 下降。在随后的 24 年随访中,有 187 例 eGFR 降低(6.3/1000 人年)和 113 例 MACE(3.6/1000 人年)事件。早期快速 eGFR 下降与 eGFR 降低的风险相关(风险比[HR]1.81,95%CI1.18-2.79,P=0.0064),但在调整基线 eGFR 水平后则没有相关性(HR0.94,95%CI0.53-1.66,P=0.84)。与复合心血管事件或 MACE 无相关性。
在主要具有正常 eGFR 和正常白蛋白尿的 1 型糖尿病患者中,eGFR 斜率在个体当前水平之外,与肾脏或心血管结局没有额外的相关性。